FFG
CRVS icon

Fortem Financial Group’s Corvus Pharmaceuticals CRVS Stock Holding History

Fortem Financial Group’s Portfolio CRVS Stock Details CRVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-11,000
Closed -$19.6K – 171
2024
Q1 		$19.6K Buy
+11,000
New +$23K 0.01% 165

Other funds holding CRVS

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ASP
Adams Street Partners Chicago, Illinois $443M AUM 49.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TL
TowerView LLC New York $152M AUM 20.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fortem Financial Group's CRVS Position: Q2 2024 in Review

Fortem Financial Group sold out of Corvus Pharmaceuticals (CRVS) in Q2 2024, closing a stake of 11,000 shares — an estimated $19.6K sold.

Fortem Financial Group first reported a position in CRVS in Q1 2024 and held it in 1 quarter. The position peaked at $19.6K in Q1 2024. 47 funds tracked by Wall St. Rank hold CRVS as of Q2 2024.

  • Fortem Financial Group reported no remaining Corvus Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • Fortem Financial Group sold 11,000 Corvus Pharmaceuticals shares in Q2 2024, an estimated $19.6K.
  • Fortem Financial Group first reported a position in Corvus Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • Fortem Financial Group's Corvus Pharmaceuticals position peaked at $19.6K in Q1 2024.
  • 47 funds tracked by Wall St. Rank held Corvus Pharmaceuticals as of Q2 2024.

Based on Fortem Financial Group's 13F filing for Q2 2024, filed 2 Aug 2024.